Table of Contents

company-logo

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Dividend Announcement

• Galectin Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Galectin Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Galectin Therapeutics Dividend History

Galectin Therapeutics Dividend Yield

Galectin Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Galectin Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Galectin Therapeutics Financial Ratios

P/E ratio-3.74
PEG ratio-0.41
P/B ratio-1.79
ROE58.60%
Payout ratio-0.47%
Current ratio1.13
Quick ratio1.13
Cash Ratio1.07

Galectin Therapeutics Dividend FAQ

Does Galectin Therapeutics stock pay dividends?
Galectin Therapeutics does not currently pay dividends to its shareholders.
Has Galectin Therapeutics ever paid a dividend?
No, Galectin Therapeutics has no a history of paying dividends to its shareholders. Galectin Therapeutics is not known for its dividend payments.
Why doesn't Galectin Therapeutics pay dividends?
There are several potential reasons why Galectin Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Galectin Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Galectin Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Galectin Therapeutics a dividend aristocrat?
Galectin Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Galectin Therapeutics a dividend king?
Galectin Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Galectin Therapeutics a dividend stock?
No, Galectin Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Galectin Therapeutics stocks?
To buy Galectin Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Galectin Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.